SAR-442970 is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II drugs for Hidradenitis Suppurativa have a 44% phase ...

Sanofi SA (Nasdaq: SNY) will pay Cytokinetics an undisclosed amount and take over exclusive rights of the drug — aimed at a genetic heart wall-thickening disease known as hypertrophic ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine program into phase 3. The move follows a phase 2 win last ...

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health ...

Investing.com -- Shares of Cytokinetics (NASDAQ:CYTK), Incorporated (NASDAQ:CYTK) climbed 4.8% after the company announced that Sanofi (NASDAQ:SNY) will acquire exclusive rights to develop and ...

As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate. The rights will be transferred from ...

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Sanofi will acquire exclusive rights to develop and commercialize ...

Teva Pharmaceuticals’TEVA0.63%increase; green up pointing triangle shares soared and Sanofi’sSAN-0.33%decrease; red down pointing triangle stock moved higher following positive results from ...

17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they would collaborate on developing a ...

On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC ...